Welcome to our dedicated page for Elicio Therapeutics news (Ticker: ELTX), a resource for investors and traders seeking the latest updates and insights on Elicio Therapeutics stock.
Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company developing a pipeline of investigational cancer immunotherapies built on its Amphiphile (AMP) platform. This news page aggregates company press releases and market-moving updates related to Elicio’s clinical programs, platform research, and corporate developments.
Recent news from Elicio has focused on its lead program ELI-002, an AMP-based, off-the-shelf immunotherapy targeting cancers driven by KRAS mutations. The company regularly reports immunogenicity data from the Phase 2 AMPLIFY-7P trial in mKRAS pancreatic ductal adenocarcinoma, including mKRAS-specific T cell response rates, CD4 and CD8 activation, antigen spreading to non-mKRAS neoantigens, and analyses across diverse HLA backgrounds. These updates provide insight into how ELI-002 7P may elicit broad, mutation-directed immune responses in high-risk patients.
In addition to clinical readouts, Elicio’s news flow includes announcements about preclinical findings for intratumoral ELI-004, presentations at scientific meetings such as the Society for Immunotherapy of Cancer and ESMO Immuno-Oncology Congress, and investigator-initiated trials combining ELI-002 7P with chemotherapy and checkpoint inhibitors in pancreatic cancer. Corporate updates, including financial results, cash runway commentary, and executive appointments, also feature prominently in the company’s disclosures.
Investors and observers following ELTX news can use this page to review Elicio’s latest statements on its AMP platform, off-the-shelf immunotherapy strategy, and development plans in mKRAS-positive pancreatic and colorectal cancers, as well as emerging programs targeting BRAF and p53 mutations. Bookmark this feed to monitor new trial data, regulatory-related communications, and other material events reported by the company.
Elicio Therapeutics (Nasdaq: ELTX) announced that CEO Robert Connelly and CSO Pete DeMuth will present at the TD Cowen 46th Annual Health Care Conference in Boston, March 2-4, 2026. The company presentation is scheduled for March 4, 2026 at 1:10 PM ET.
According to Elicio, a live webcast and a 90-day replay will be available on the company Events page for investors who cannot attend in person.
Elicio Therapeutics (Nasdaq: ELTX) granted an aggregate of 30,300 inducement stock options on February 17, 2026, to a newly hired employee under its 2024 Inducement Incentive Award Plan.
The options have an exercise price of $8.59 per share (Nasdaq close on Feb 17, 2026) and vest over four years with 25% vesting after one year and monthly vesting thereafter, subject to continued service.
Elicio Therapeutics (Nasdaq: ELTX) announced on January 16, 2026 that on January 15, 2026 it granted an aggregate of 22,400 inducement stock options to two new employees under the 2024 Inducement Incentive Award Plan as permitted by Nasdaq Listing Rule 5635(c)(4). The grants were approved by the Compensation Committee and set the exercise price at $7.81 per share, the Nasdaq closing price on the grant date. The options vest over four years with 25% vesting on the first anniversary of each employee’s start date and the remainder vesting ratably each month thereafter, subject to continued service.
Elicio Therapeutics (Nasdaq: ELTX) announced on December 16, 2025 that on December 15, 2025 it granted an aggregate of 157,193 inducement stock options to three new employees under the 2024 Inducement Incentive Award Plan.
The option exercise price is $8.52 per share, equal to the Nasdaq closing price on December 15, 2025. Grants were approved by the Compensation Committee and issued as inducements under Nasdaq Listing Rule 5635(c)(4). The awards vest over four years: 25% on the first anniversary of each start date, then the remainder vesting ratably monthly subject to continued service.
Elicio Therapeutics (Nasdaq: ELTX) reported that analysis from a subset of the Phase 2 AMPLIFY-7P trial showed antigen spreading beyond targeted mKRAS antigens after ELI-002 7P treatment.
Key results: 87% (13/15) of evaluated patients showed T cell responses to non-mKRAS neoantigens; among 90 treated patients, 99% (89/90) had mKRAS T cell responses; median fold change for antigen spreading in Phase 2 was 10.6x and 90% of assessed patients showed responses in both CD4 and CD8 T cells.
Elicio Therapeutics (Nasdaq: ELTX) appointed Marc J. Wolfgang as Chief Technology Officer on Nov 19, 2025 to lead CMC, technical development, manufacturing, quality, and supply chain.
Mr. Wolfgang brings >30 years of experience across cell therapy, biologics, nucleic-acid medicines, vaccines, and LNP platforms and previously held senior roles at Sail Biomedicines, BioNTech, Biogen, and others. His hire aligns with preparations for potential late‑stage and commercial readiness ahead of the ELI-002 7P disease‑free survival analysis expected 1H 2026.
Elicio Therapeutics (Nasdaq: ELTX) reported Q3 2025 results and clinical updates on Nov 13, 2025. The company now expects the event-driven primary DFS analysis in 1H 2026 after observing fewer than projected disease progressions and deaths in the Phase 2 AMPLIFY-7P trial. Updated data show strong immunogenicity: 99% (89/90) mKRAS-specific T cell responses and 86.8% cytotoxic responses in evaluable patients. IDMC recommended continuing the trial with no modifications and confirmed a favorable safety profile. Q3 net loss narrowed to $10.1M and cash and equivalents were $20.6M as of Sept 30, 2025; ~$11.1M gross was raised via ATM in Q3, supporting operations through Q2 2026.
Elicio Therapeutics (Nasdaq: ELTX) reported updated immunogenicity from the Phase 2 AMPLIFY-7P trial of ELI-002 7P and preclinical intratumoral data for ELI-004 presented at SITC (Nov 7, 2025).
Key clinical highlights: 99% of 90 evaluable patients mounted mKRAS-specific T cell responses (mean 145-fold increase), 86.8% (66/76) induced cytotoxic responses, 85% showed combined CD4/CD8 activation, and 88% responded to their own tumor mutation. HLA typing across 89 patients found 1,132 unique alleles with no clear HLA-specific loss of response. Preclinical ELI-004 intratumoral dosing eradicated tumors in >90% of mice and conferred long-term protection.
Elicio Therapeutics (Nasdaq: ELTX) will present clinical and preclinical data at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting, Nov 5–9, 2025, in National Harbor, MD.
Two poster presentations include a late-breaking abstract reporting immunogenicity results from the ongoing Phase 2 AMPLIFY-7P trial of ELI-002 in mKRAS-driven pancreatic cancer (Abstract 1317; Nov 7, 2025) and preclinical data for ELI-004 showing AMP-immunomodulator activity in syngeneic solid tumor models (Abstract 946; Nov 8, 2025).
Elicio Therapeutics (Nasdaq: ELTX) reported preliminary Phase 2 AMPLIFY-7P results showing that ELI-002 7P induced mKRAS-specific T cell responses across diverse HLA backgrounds.
Among 89 patients, 1,132 unique HLA types were identified out of 1,398 total HLA types assessed, and 99% (88/89) of patients assessed for HLA background mounted mKRAS-specific T cell responses after treatment. The company said these findings suggest mKRAS antigens can be presented across many HLA alleles, implying potential applicability to a broad population of pancreatic ductal adenocarcinoma (PDAC) patients.
Results are described as preliminary and come from an ongoing Phase 2 study; additional data and follow-up were not provided.